Production (Stage)
IGC Pharma, Inc.
IGC
$0.3808
-$0.0342-8.24%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.27M | 1.24M | 1.18M | 1.06M | 1.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.27M | 1.24M | 1.18M | 1.06M | 1.35M |
| Cost of Revenue | 652.00K | 600.00K | 518.00K | 421.00K | 612.00K |
| Gross Profit | 619.00K | 636.00K | 665.00K | 641.00K | 733.00K |
| SG&A Expenses | 4.43M | 6.05M | 7.15M | 7.50M | 7.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.74M | 10.16M | 11.23M | 11.84M | 11.87M |
| Operating Income | -7.47M | -8.92M | -10.04M | -10.78M | -10.52M |
| Income Before Tax | -7.12M | -8.81M | -12.57M | -13.30M | -13.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.12 | -8.81 | -12.57 | -13.30 | -13.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.12M | -8.81M | -12.57M | -13.30M | -13.00M |
| EBIT | -7.47M | -8.92M | -10.04M | -10.78M | -10.52M |
| EBITDA | -6.85M | -8.30M | -9.41M | -10.13M | -9.89M |
| EPS Basic | -0.09 | -0.12 | -0.19 | -0.21 | -0.22 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.09 | -0.11 | -0.11 |
| EPS Diluted | -0.09 | -0.12 | -0.19 | -0.21 | -0.22 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.09 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 306.04M | 290.70M | 276.79M | 255.08M | 235.35M |
| Average Diluted Shares Outstanding | 306.04M | 290.70M | 276.79M | 255.08M | 235.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |